✦ LIBER ✦

Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer

✍ Scribed by Mark T. Fleming; Guru Sonpavde; Michael Kolodziej; Sanjay Awasthi; Thomas E. Hutson; Danko Martincic; Ashutosh Rastogi; Steven R. Rousey; Ralph E. Weinstein; Matthew D. Galsky; William R. Berry; Yunfei Wang; Kristi A. Boehm; Lina Asmar; Mary A. Rauch; Tomasz M. Beer

Book ID: 113539001
Publisher: CIG Media Group, LP.
Year: 2012
Tongue: English
Weight: 434 KB
Volume: 10
Category: Article
ISSN: 1558-7673
DOI: 10.1016/j.clgc.2011.11.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomised phase II study of siltuximab

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

✍ K. Fizazi; J.S. De Bono; A. Flechon; A. Heidenreich; E. Voog; N.B. Davis; Ming Q 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 336 KB

4025 POSTER A phase I/II study of suniti

4025 POSTER A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)

✍ A. Zurita; N.D. Shore; M.F. Kozloff; C.W. Ryan; T.M. Beer; E. Chow Maneval; I. C 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Final safety and efficacy analysis of th

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial

✍ Nicholas D. James; Armelle Caty; Heather Payne; Michael Borre; Bernard A. Zonnen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB